NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Technology Appraisal Committee D meeting minutes

**Minutes:** Confirmed

**Date:** Wednesday 12 July 2023

**Location:** Zoom

## Attendees

Committee members present

1. Dr Megan John (Chair Topic 2) Items 1 to 5.2.2
2. Dr Stephen Smith (Chair Topics 1 & 3) Present for all items
3. Martin Bradley Present for all items
4. Dr Matthew Bradley Items 5 to 6.2.2
5. Emtiyaz Chowdhury Items 5 to 5.2.2
6. Elliott Dash Items 4.1.3 to 6.2.2
7. Professor Sofia Dias Present for all items
8. Dr Steve Edwards Items 1 to 4.1.3
9. Andrew Fox Items 1 to 5.1.3
10. Tina Garvey Items 1 to 4.2.2
11. Christopher Herring Present for all items
12. Dr Andrew Hitchings Present for all items
13. Dr Robert Hodgson Items 1 to 4.2.2
14. Dr Guy Makin Present for all items
15. Dr Philip Mallender Present for all items
16. Professor David Meads Present for all items
17. Giles Monnickendam Present for all items
18. Dr Nathan Moore Items 1 to 6.1.3
19. Stella O’Brien Present for all items
20. Dr Malcolm Oswald Present for all items
21. Carole Pitkeathley Items 1 to 6.1.3
22. Alan Thomas Present for all items

NICE staff (key players) present

Linda Landells, Associate Director Items 1 to 5.2.2

Jasdeep Hayre, Associate Director Items 6 to 6.2.2

Louise Jafferally, Project Manager Items 1 to 4.2.2

Celia Mayers, Project Manager Items 5 to 6.2.2

Caron Jones, Heath Technology Assessment Adviser Items 1 to 4.2.2

Victoria Kelly, Heath Technology Assessment Adviser Items 5 to 5.2.2

Lizzie Walker, Heath Technology Assessment Adviser Items 6 to 6.2.2

Cara Gibbons, Heath Technology Assessment Analyst Items 1 to 4.2.2

Dilan Savani, Heath Technology Assessment Analyst Items 5 to 5.2.2

Alice Pritchard, Heath Technology Assessment Analyst Items 6 to 6.2.2

External assessment group representatives present

Robert Wolff, Kleijnen Systematic Reviews Ltd (KSR) Items 1 to 4.1.3

Willem Witlox, Kleijnen Systematic Reviews Ltd (KSR) Items 1 to 4.1.3

Caroline Farmer, Peninsula Technology Assessment Group, University of Exeter (PenTAG) Items 5 to 5.1.3

Ed Wilson, Peninsula Technology Assessment Group, University of Exeter (PenTAG)

Items 5 to 5.1.3

Jo Lord, Southampton Health Technology Assessment Centre (SHTAC) Items 6 to 6.1.3

Geoff Frampton, Southampton Health Technology Assessment Centre (SHTAC)

Items 6 to 6.1.3

Clinical, Patient & NHS England experts present

Professor Peter Clark, Cancer Drug Fund Clinical Lead, NHS England, Items 1 to 4.2.2 & 6 to 6.2.2

Dr Kai-Keen Shiu, Consultant Medical Oncologist, clinical expert nominated by MSD, Items 1 to 4.1.3

Helen Morement, Patient expert, nominated by AMMF, The Cholangiocarcinoma Charity, Items 1 to 4.1.3

Andrea Sheardown, Patient expert, nominated by AMMF, The Cholangiocarcinoma Charity, Items 1 to 4.1.3

Sanjeev Patel, Dr Sanjeev Patel, Innovative Medicines Fund Clinical lead, NHS England, Items 5 to 5.1.3

Ross Bennett, Patient expert, nominated by The Haemophilia Society, Items 5 to 5.1.3

John Curley, Patient expert, nominated by The Haemophilia Society, Items 5 to 5.1.3

Priyanka Raheja, Consultant Haematologist, clinical expert, nominated by CSL Behring, Items 5 to 5.1.3

Charles Percy, Consultant Haematologist, clinical expert nominated by NHS England, Items 5 to 5.1.3

Claire Harrison, Professor of myeloproliferative neoplasms and clinical director, clinical expert nominated by Novartis & MPN Voice, Items 6 to 6.1.3

Tim Somervaille, Professor of Haematological Oncology, clinical expert nominated by Novartis, Items 6 to 6.1.3

Charlotte Crowley, Policy and Evidence Manager, patient expert nominated by Leukaemia Care, Items 6 to 6.1.3

*Please note that alongside the attendees listed in this document, there were additional NICE Staff present in this meeting. These attendees were not involved in the decision making or discussions.*

## Minutes

### Introduction to the meeting

* 1. The chair Dr Stephen Smith welcomed members of the committee and other attendees present to the meeting.
  2. The chair noted apologies from Dr Ben Searle, Dr Bernard Khoo, Professor Chris Parker, Dr Ivan Koychev, Professor John Watkins, Professor Rachel Elliott, Dr Raju Reddy and Dr Rebecca Payne.

### News and announcements

* 1. None

### Minutes from the last meeting

* 1. The committee approved the minutes of the committee meeting held on Wednesday 14 June 2023.

### Appraisal of pembrolizumab for previously treated solid tumours with high microsatellite instability or mismatch repair deficiency [ID4036]

* 1. Part 1 – Open session
     1. The chair welcomed the invited experts, external assessment group representatives, members of the public and company representatives from MSD.
     2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered. Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here.](https://www.nice.org.uk/guidance/indevelopment/gid-ta11038/documents)
     3. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Professor David Meads, Dr Guy Makin and Malcolm Oswald.
  2. Part 2 – Closed session (company representatives, clinical and patient experts, external assessment group representatives and members of the public were asked to leave the meeting)
     1. The committee then agreed on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG). The committee decision was reached by consensus.
     2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) or Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta11038>.

### Appraisal of etranacogene dezaparvovec for treating moderately severe or severe haemophilia B [ID3812]

* 1. Part 1 – Open session
     1. The chair Dr Megan John welcomed the invited experts, external assessment group representatives, members of the public and company representatives from CSL Behring.
     2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered. Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here.](https://www.nice.org.uk/guidance/indevelopment/gid-ta10699/documents)
     3. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Malcolm Oswald and Philip Mallender.
  2. Part 2 – Closed session (company representatives, experts, external assessment group representatives and members of the public were asked to leave the meeting)
     1. The committee then agreed on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG). The committee decision was reached by consensus.
     2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) or Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10699>.

### Appraisal of ruxolitinib for treating polycythaemia vera - review of TA356 [ID5106]

* 1. Part 1 – Open session
     1. The chair Dr Stephen Smith welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Novartis.
     2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered. Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here.](https://www.nice.org.uk/guidance/indevelopment/gid-ta11079/documents)
     3. The Chair led a discussion of the consultation comments presented to the committee.
  2. Part 2 – Closed session (company representatives, clinical and patient experts, external assessment group representatives and members of the public were asked to leave the meeting)
     1. The committee then agreed on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG). The committee decision was reached by consensus.
     2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) or Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta11079>.

### Date of the next meeting

The next meeting of the Technology Appraisal Committee D will be held as a hybrid meeting on Thursday 10 August 2023.